This study aims to evaluate the effect of Helicobacter pylori eradication on gastrointestinal symptoms in adult patients. H. pylori infection is a common cause of dyspepsia and other upper gastrointestinal complaints. The trial will assess whether successful eradication therapy leads to significant improvement in symptoms compared to baseline. Adult patients diagnosed with H. pylori infection will receive standard eradication treatment, and symptom changes will be monitored using validated questionnaires over a defined follow-up period.

Inclusion Criteria:

1. Adults aged 18 years and older.
2. Confirmed diagnosis of Helicobacter pylori infection by one or more diagnostic tests.
3. Presence of any upper or lower gastrointestinal symptoms.
4. Willingness to undergo H. Pylori eradication therapy and follow-up.
5. Ability to provide informed consent.

Exclusion Criteria:

1. Age less than 18 years.
2. The previously unsuccessful application of empirical H. pylori eradication therapy.
3. Use of non-steroidal anti-inflammatory drugs (NSAIDs).
4. Any malignant disease of the stomach or any other site.
5. Any associated comorbidity (renal insufficiency, mental illness).
6. History of allergies to proton pump inhibitors or antibiotics.
7. Refusal to participate in the survey.

Adult patients (≥18 years) diagnosed with Helicobacter pylori infection by invasive or non-invasive tests (urea breath test or stool antigen test) and who have completed standard eradication therapy prescribed by their healthcare providers. The population includes both male and female patients presenting with gastrointestinal symptoms such as dyspepsia.